Pharmacokinetics of inhibition of adenosine deaminase by erythro-9-(2-hydroxy-3-nonyl)adenine in CBA mice.
The pharmacokinetics of erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) inhibition of adenosine deaminase (ADA) was measured in vivo in CBA mice. The in vivo assay utilized injection of 10-100 nmoles [2-3H]adenosine and measurement of blood 3H2O 20 min later. A single oral dose of EHNA (50 mg/kg) totally inhibited ADA for 4 hr and caused a large increase in conversion of [2-3H]adenosine to [2-3H]ATP. EHNA (3 mg/kg) decreased deamination by 50% for 2-6 hr, depending on the dose of adenosine used. Mice dosed with EHNA (100 mg/kg) once daily for 7 days showed the same ADA recovery rate as mice dosed only once. High single oral doses of EHNA had no effect on blood ATP and GTP pools.
D000225:Adenine / Q000031:analogs & derivatives* / Q000494:pharmacology; D058892:Adenosine Deaminase Inhibitors; D000255:Adenosine Triphosphate / Q000097:blood; D000818:Animals; D004305:Dose-Response Relationship, Drug; D004912:Erythrocytes / Q000378:metabolism; D006160:Guanosine Triphosphate / Q000097:blood; D007700:Kinetics; D051379:Mice; D008808:Mice, Inbred CBA; D009700:Nucleoside Deaminases / Q000037:antagonists & inhibitors*
D058892:Adenosine Deaminase Inhibitors; C010192:9-(2-hydroxy-3-nonyl)adenine; D006160:Guanosine Triphosphate; D000255:Adenosine Triphosphate; D009700:Nucleoside Deaminases; D000225:Adenine